ILA-CM14R-100μg / 询价
ILA-CM14R-500μg / 询价
ILA-CM14R-500μgx2 / 询价
Cynomolgus IL-4 R alpha/CD124 Protein
Recombinant Cynomolgus IL-4 R alpha/CD124 Protein is expressed from HEK293 with His tag at the C-Terminus.It contains Met26-Arg232 [Accession | G7Q0S7].
The protein has a predicted MW of 24.84 kDa. Due to glycosylation, the protein migrates to 45-60 kDa based on Bis-Tris PAGE result.
>95% as determined by Bis-Tris PAGE
>95% as determined by HPLC
Less than 1 EU per μg by the LAL method.
Lyophilized from 0.22 μm filtered solution in PBS (pH 7.4). Normally 8% trehalose is added as protectant before lyophilization.
Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/ml is recommended. Dissolve the lyophilized protein in distilled water.
-20 to -80°C for 12 months as supplied from date of receipt.
-80°C for 3 months after reconstitution.
Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Cynomolgus IL-4 R alpha on Bis-Tris PAGE under reduced condition. The purity is greater than 95%.
The purity of Cynomolgus IL-4 R alpha is greater than 95% as determined by SEC-HPLC.
Immobilized Human IL-4, No Tag at 5 μg/ml (100 μl/well) on the plate. Dose response curve for Cynomolgus IL-4 R alpha, His Tag with the EC50 of 97.8 ng/ml determined by ELISA (QC Test).
Cynomolgus IL-4, His Tag immobilized on CM5 Chip can bind Cynomolgus IL-4 R alpha, His Tag with an affinity constant of 13.48 nM as determined in SPR assay (Biacore T200).
Interleukin 4 Receptor alpha (IL-4 Ra), also known as CD124 and BSF receptor, is a widely expressed 140 kDa transmembrane glycoprotein in the class I cytokine receptor family. The effects of IL-4 are mediated after binding to high affinity receptor complexes present on hematopoietic as well as non-hematopoietic cells.
CD124; IL-4 R alpha; IL-4R subunit alpha; IL4R; IL-4Ra; IL4RACD124
(1) Ghoreschi K , Thomas P , Breit S , et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoimmune disease[J]. Nature Medicine, 2002, 9(1):40-46.
